Philadelphia, Pennsylvania 19104


Purpose:

The purpose of this study is to identify and quantify circulating tumor markers, which are associated with the presence of tumors. The current imaging available does not allow specificity of tumor size as it relates to pseudoprogression (a temporary enlargement or "swelling" of the tumor after treatment before it shrinks). Our hope is that CTCs will provide a more accurate description of tumor state for high grade glioma patients.


Criteria:

Inclusion Criteria: - Patients with biopsy-proven high grade glioma who are undergoing definitive radiotherapy as a part of their treatment regimen or patients with radiographic appearance of high grade glioma - Age 18 or older - Signed informed consent Exclusion Criteria:


NCT ID:

NCT02558335


Primary Contact:

Principal Investigator
Robert Lustig, MD
Abramsvaniaon Cancer Center of the University of Pennsyl

Robert Lustig, MD
Phone: 855-216-0098
Email: PennCancerTrials@emergingmed.com


Backup Contact:

N/A


Location Contact:

Philadelphia, Pennsylvania 19104
United States

Robert Lustig, MD
Phone: 855-216-0098
Email: PennCancerTrials@emergingmed.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.